Renaissance Technologies
TERN

Renaissance Technologies’s Terns Pharmaceuticals TERN Stock Holding History

Renaissance Technologies’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.91M Sell
169,034
-297,813
-64% -$12.2M 0.01% 1027
2025
Q4 		$18.9M Sell
466,847
-209,987
-31% -$4.85M 0.03% 631
2025
Q3 		$5.08M Sell
676,834
-245,700
-27% -$1.57M 0.01% 1485
2025
Q2 		$3.44M Sell
922,534
-511,300
-36% -$1.6M ﹤0.01% 1758
2025
Q1 		$3.96M Buy
1,433,834
+810,700
+130% +$3.31M 0.01% 1562
2024
Q4 		$3.45M Buy
623,134
+143,634
+30% +$973K 0.01% 1679
2024
Q3 		$4M Buy
479,500
+392,000
+448% +$3.23M 0.01% 1584
2024
Q2 		$596K Buy
+87,500
New +$530K ﹤0.01% 2613
2023
Q4 		– Sell
-290,100
Closed -$1.46M – 4128
2023
Q3 		$1.46M Buy
290,100
+236,900
+445% +$1.5M ﹤0.01% 2054
2023
Q2 		$466K Sell
53,200
-52,000
-49% -$606K ﹤0.01% 2909
2023
Q1 		$1.25M Sell
105,200
-9,700
-8% -$92.7K ﹤0.01% 2330
2022
Q4 		$1.17M Sell
114,900
-37,300
-25% -$248K ﹤0.01% 2437
2022
Q3 		$896K Sell
152,200
-32,216
-17% -$120K ﹤0.01% 2564
2022
Q2 		$457K Buy
184,416
+116,616
+172% +$233K ﹤0.01% 3210
2022
Q1 		$201K Buy
+67,800
New +$289K ﹤0.01% 3646

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Renaissance Technologies's TERN Position: Q1 2026 in Review

Renaissance Technologies reduced its Terns Pharmaceuticals (TERN) stake by 64% in Q1 2026, selling an estimated $12.2M and leaving 169,034 shares worth $8.91M. The position accounts for 0.01% of the portfolio, ranked #1027.

Renaissance Technologies first reported a position in TERN in Q1 2022 and has held it in 15 quarters since. The position peaked at $18.9M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Renaissance Technologies held 169,034 shares of Terns Pharmaceuticals worth $8.91M as of Q1 2026.
  • Renaissance Technologies sold 297,813 Terns Pharmaceuticals shares in Q1 2026, an estimated $12.2M.
  • Terns Pharmaceuticals made up 0.01% of Renaissance Technologies's portfolio in Q1 2026, its #1027 holding.
  • Renaissance Technologies first reported a position in Terns Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
  • Renaissance Technologies's Terns Pharmaceuticals position peaked at $18.9M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.